Microbix Announces Results of Vote to Elect Directors

TORONTO, March 6, 2014 /CNW/ - Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"), an innovator of biological products and technologies, is pleased to announce that each of the nominees proposed as directors in the management information circular dated January 31, 2014 was duly elected as a director of Microbix by a majority of the votes cast by shareholders present in person or by proxy at the Annual Meeting of Shareholders held in Toronto, Ontario on March 5, 2014.

The voting results are detailed below:

Nominee			For			% For			Withheld			% Withheld
Peter M. Blecher			28,333,628			99.42			165,585			0.58
Mark A. Cochran			27,683,328			97.14			815,885			2.86
Vaughn C. Embro-Pantalony			28,334,213			99.42			165,000			0.58
William J. Gastle			28,334,913			99.42			164,300			0.58
Andrew C. Pollock			28,199,713			98.95			299,500			1.05
Joseph D. Renner			28,333,628			99.42			165,585			0.58
Martin Marino			28,336,213			99.43			163,000			0.57
Cameron Groome			28,199,713			98.95			299,500			1.05

About Microbix Biosystems
Microbix Biosystems Inc. specializes in the development of biological solutions, including products for vaccine and diagnostics markets worldwide.  The company owns intellectual property for an approved biological drug, a vaccine technology and an animal reproduction technology.  Established in 1988, Microbix is headquartered in Toronto.

Microbix' pipeline of innovative technologies and products includes LumiSort® semen sexing technology for the livestock industry, Kinlytic®, a thrombolytic drug with several approved and potential applications including the treatment of life-threatening blood clots, and VIRUSMAX®, a proprietary technology for increasing virus yields in influenza vaccine manufacture.

Please visit www.sedar.com for recent Microbix Biosystems Inc. filings on its pipeline products and financial information.

 

SOURCE: Microbix Biosystems Inc.

Visit www.microbix.com or contact:  Vaughn C. Embro-Pantalony, CEO, [phone] (ext. 350) or Charles Wallace, CFO [phone] (ext. 255).